Diabetes mellitus is one of the most significant worldwide health challenges, which has to be constantly monitored, provided with personalized treatment, and behavioral changes. Although effective, traditional management approaches are usually constrained by slow clinical decision-making, therapeutic inertia, and poor patient compliance. The collaboration of artificial intelligence (AI) and digital therapeutics (DTx) is a paradigm shift in the context of precision, predictive, and patient-centered diabetes care. Machine learning algorithms and deep neural networks are artificial intelligence-based technologies becoming more integrated into continuous glucose monitoring systems, automated insulin delivery platforms, and predictive excursions of glycemic profile, optimal insulin dosing, and better time-in-range parameters. Adaptive insulin modulation in closed-loop systems like the Medtronic MiniMed 780G and Tandem t: slim X2 has shown that there are substantial improvements in the HbA1c and the number of hypoglycemic episodes. In addition, AI-based diagnostic systems such as the IDx-DR allow detecting diabetic retinopathy early, which builds up preventative care. The digital therapeutics platform offers evidence-based and structured behavioral therapy to encourage lifestyle change, medication adherence, and remote patient monitoring. Digitally delivered programs have been reported to have enhanced clinically significant glycemic control and cardiometabolic risk factors in companies like Omada Health and Virta Health. In spite of these improvements, there are still some challenges, such as the problem of data privacy, bias in algorithms, regulatory issues, and access inequality. The future directions will include fully autonomous closed-loop systems, the integration of multi-omics data to enable precision endocrinology, and drug discovery with the assistance of AI. To sum up, AI and digital therapeutics are transforming the way diabetes is managed today by empowering proactive, patient-centered, and technology-based care models that promise to yield greater benefits in the long term by decreasing the burden of diabetes around the globe.

To be updated